Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;209(4):130-7.
doi: 10.1016/j.cancergen.2015.12.013. Epub 2016 Jan 12.

Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort

Charité Ricker  1 , Julie O Culver  2 , Katrina Lowstuter  2 , Duveen Sturgeon  2 , Julia D Sturgeon  2 , Christopher R Chanock  2 , William J Gauderman  3 , Kevin J McDonnell  4 , Gregory E Idos  4 , Stephen B Gruber  5
Affiliations

Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort

Charité Ricker et al. Cancer Genet. 2016 Apr.

Abstract

This study aims to assess multi-gene panel testing in an ethnically diverse clinical cancer genetics practice. We conducted a retrospective study of individuals with a personal or family history of cancer undergoing clinically indicated multi-gene panel tests of 6-110 genes, from six commercial laboratories. The 475 patients in the study included 228 Hispanics (47.6%), 166 non-Hispanic Whites (35.4%), 55 Asians (11.6%), 19 Blacks (4.0%), and seven others (1.5%). Panel testing found that 15.6% (74/475) of patients carried deleterious mutations for a total of 79 mutations identified. This included 7.4% (35/475) of patients who had a mutation identified that would not have been tested with a gene-by-gene approach. The identification of a panel-added mutation impacted clinical management for most of cases (69%, 24/35), and genetic testing was recommended for the first degree relatives of nearly all of them (91%, 32/35). Variants of uncertain significance (VUSs) were identified in a higher proportion of tests performed in ethnic minorities. Multi-gene panel testing increases the yield of mutations detected and adds to the capability of providing individualized cancer risk assessment. VUSs represent an interpretive challenge due to less data available outside of White, non-Hispanic populations. Further studies are necessary to expand understanding of the implementation and utilization of panels across broad clinical settings and patient populations.

Keywords: Hereditary cancer; cancer risk assessment; ethnic minorities; multi-gene panels; variants of uncertain significance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The other co-authors do not have any potential conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Mutations detected in 475 patients, overall and by cancer site, illustrating yield of panels *Patient(s) with both a target mutation and panel-detected mutation are included in both categories
Figure 2
Figure 2
(a) Percentage of tests with a mutation identified as the number of genes on a panel test increases. (b) Percentage of tests with a variant of uncertain significance identified as the number of genes on a panel test increases.
Figure 2
Figure 2
(a) Percentage of tests with a mutation identified as the number of genes on a panel test increases. (b) Percentage of tests with a variant of uncertain significance identified as the number of genes on a panel test increases.
See this image and copyright information in PMC

References

    1. Laduca H, Stuenkel aJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014;16:1–8. - PMC - PubMed
    1. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet. 2014 - PMC - PubMed
    1. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121:25–33. - PubMed
    1. Yurgelun MB, Allen B, Kaldate RR, et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients with Suspected Lynch Syndrome. Gastroenterology. 2015 - PMC - PubMed
    1. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med. 2014;16:407–412. - PubMed

Publication types